Prestige Biologics Recruits CDMO Sales Expert Formerly at Lonza

Prestige Biologics, a Contract Development and Manufacturing Organization (CDMO) company specializing in biopharmaceuticals, announced on the 10th that it has recruited Fionn Huang, formerly of global pharmaceutical company Lonza, as the Director of its Global Business Development (B.D.) Center.

Prestige Biologics plans to establish and implement new sales strategies aligned with the evolving CDMO market trends, centering on Director Fionn Huang, a Singaporean national well-versed in the Chinese market. Director Huang will actively conduct overseas sales activities across the Asia-Pacific region, including China. Domestically, since March, the newly established 'U.S. Biosecurity Act Response TFT' has been responding to new demand by employing a two-track approach, including visits to the headquarters in Osong, Chungbuk, to find alternative Chinese CDMO companies.

Director Fionn Huang is recognized as an expert with over 15 years of extensive experience overseeing process and business development, as well as sales management in the global CDMO industry. He earned a Bachelor of Science in Biomedical Sciences from the National University of Singapore (NUS) and an Executive MBA from the Quantic School of Business and Technology in the U.S. He has worked at Lonza, Merck, and Thermo Fisher. At Lonza, the world’s leading global CDMO company, he spent 10 years covering quality assurance, production, GMP certification, marketing, and sales at its U.S. headquarters and Singapore branch. Subsequently, at global big pharma Merck, he served as CDMO Sales Director for clients in the Asia-Pacific region, including China, and at U.S. biotech company Thermo Fisher, he worked as a sales leader handling automation of biopharmaceutical production facilities and GMP-related tasks.

Prestige Biologics expects that the recruitment of Director Fionn Huang will accelerate CDMO sales in the U.S. and China. Director Huang plans to target the Chinese market leveraging his fluency in English and Chinese, as well as his extensive experience and network from long-term work at global CDMO companies’ branches in China and Singapore. In particular, the strategy focuses on securing orders from Chinese CDMO companies, including Wuxi Biologics, which the U.S. restricts from trading.

Director Fionn Huang stated, “I will combine the broad network and biopharmaceutical production experience accumulated over many years at global pharmaceutical companies with K-Bio to create diverse business opportunities.”

Prestige Biologics said, “The recruitment of Director Fionn Huang, who can be called a China expert, is a proactive and preemptive company response strategy to the U.S. Biosecurity Act issue. We are sequentially preparing for full factory operation by securing additional global sales experts and operational personnel.”

This content was produced with the assistance of AI translation services.